<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Dangerous Words in a Biotech Lab: "Let's just build a custom tool." - Mingsheng Qi</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        :root {
            --bg-dark: #0a0e27;
            --bg-card: #1a1f3a;
            --accent-blue: #00d4ff;
            --accent-green: #00ff88;
            --accent-purple: #b24bf3;
            --text-primary: #ffffff;
            --text-secondary: #a0a6c9;
        }

        body {
            font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
            background: var(--bg-dark);
            color: var(--text-primary);
            line-height: 1.8;
        }

        nav {
            position: fixed;
            top: 0;
            width: 100%;
            background: rgba(10, 14, 39, 0.95);
            backdrop-filter: blur(10px);
            padding: 1.5rem 5%;
            z-index: 1000;
            border-bottom: 1px solid rgba(0, 212, 255, 0.1);
        }

        nav ul {
            list-style: none;
            display: flex;
            justify-content: center;
            gap: 3rem;
            flex-wrap: wrap;
        }

        nav a {
            color: var(--text-secondary);
            text-decoration: none;
            font-weight: 500;
            transition: all 0.3s;
        }

        nav a:hover {
            color: var(--accent-blue);
        }

        .back-btn {
            display: inline-flex;
            align-items: center;
            gap: 0.5rem;
            padding: 0.8rem 1.5rem;
            background: var(--bg-card);
            border: 1px solid var(--accent-blue);
            border-radius: 8px;
            color: var(--accent-blue);
            text-decoration: none;
            font-weight: 600;
            transition: all 0.3s;
            margin-bottom: 2rem;
        }

        .back-btn:hover {
            background: var(--accent-blue);
            color: var(--bg-dark);
            transform: translateX(-5px);
        }

        article {
            max-width: 800px;
            margin: 0 auto;
            padding: 8rem 5% 5rem;
        }

        .article-header {
            margin-bottom: 3rem;
        }

        .article-category {
            display: inline-block;
            padding: 0.5rem 1rem;
            background: linear-gradient(135deg, var(--accent-purple), var(--accent-blue));
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 600;
            margin-bottom: 1.5rem;
        }

        h1 {
            font-size: clamp(2rem, 5vw, 3rem);
            line-height: 1.2;
            margin-bottom: 1rem;
            background: linear-gradient(135deg, var(--accent-blue), var(--accent-green));
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        .article-meta {
            color: var(--text-secondary);
            font-size: 0.95rem;
            display: flex;
            gap: 2rem;
            flex-wrap: wrap;
            margin-bottom: 2rem;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 0.5rem;
        }

        .article-excerpt {
            font-size: 1.2rem;
            color: var(--text-secondary);
            font-style: italic;
            padding-left: 1.5rem;
            border-left: 4px solid var(--accent-blue);
            margin-bottom: 3rem;
        }

        .article-content {
            color: var(--text-secondary);
            font-size: 1.1rem;
        }

        .article-content h2 {
            color: var(--text-primary);
            font-size: 2rem;
            margin-top: 3rem;
            margin-bottom: 1.5rem;
            position: relative;
            padding-bottom: 0.5rem;
        }

        .article-content h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: linear-gradient(90deg, var(--accent-blue), var(--accent-green));
        }

        .article-content h3 {
            color: var(--accent-blue);
            font-size: 1.5rem;
            margin-top: 2rem;
            margin-bottom: 1rem;
        }

        .article-content h4 {
            color: var(--accent-green);
            font-size: 1.2rem;
            margin-top: 1.5rem;
            margin-bottom: 0.8rem;
        }

        .article-content p {
            margin-bottom: 1.5rem;
        }

        .article-content ul, .article-content ol {
            margin-bottom: 1.5rem;
            padding-left: 2rem;
        }

        .article-content li {
            margin-bottom: 0.8rem;
        }

        .article-content blockquote {
            padding: 1.5rem;
            background: var(--bg-card);
            border-left: 4px solid var(--accent-green);
            border-radius: 8px;
            margin: 2rem 0;
            font-style: italic;
        }

        .article-content strong {
            color: var(--text-primary);
            font-weight: 600;
        }

        .article-content em {
            color: var(--accent-green);
        }

        .article-content code {
            background: var(--bg-card);
            padding: 0.2rem 0.5rem;
            border-radius: 4px;
            font-family: 'Monaco', 'Courier New', monospace;
            font-size: 0.95em;
            color: var(--accent-green);
        }

        .highlight-box {
            background: var(--bg-card);
            padding: 2rem;
            border-radius: 12px;
            border: 1px solid var(--accent-blue);
            margin: 2rem 0;
        }

        .share-section {
            margin-top: 4rem;
            padding-top: 3rem;
            border-top: 1px solid rgba(0, 212, 255, 0.2);
        }

        .share-section h3 {
            color: var(--text-primary);
            margin-bottom: 1rem;
        }

        .share-buttons {
            display: flex;
            gap: 1rem;
            flex-wrap: wrap;
        }

        .share-btn {
            padding: 0.8rem 1.5rem;
            background: var(--bg-card);
            border: 1px solid var(--accent-blue);
            border-radius: 8px;
            color: var(--accent-blue);
            text-decoration: none;
            font-weight: 600;
            transition: all 0.3s;
        }

        .share-btn:hover {
            background: var(--accent-blue);
            color: var(--bg-dark);
            transform: translateY(-3px);
        }

        .related-posts {
            margin-top: 4rem;
            padding: 3rem;
            background: var(--bg-card);
            border-radius: 15px;
            border: 1px solid rgba(0, 212, 255, 0.1);
        }

        .related-posts h3 {
            color: var(--text-primary);
            margin-bottom: 2rem;
            font-size: 1.8rem;
        }

        .related-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 1.5rem;
        }

        .related-card {
            padding: 1.5rem;
            background: var(--bg-dark);
            border-radius: 10px;
            border: 1px solid rgba(0, 212, 255, 0.1);
            text-decoration: none;
            color: inherit;
            transition: all 0.3s;
        }

        .related-card:hover {
            border-color: var(--accent-green);
            transform: translateY(-5px);
        }

        .related-card h4 {
            color: var(--accent-green);
            margin-bottom: 0.5rem;
            font-size: 1.1rem;
        }

        .related-card p {
            color: var(--text-secondary);
            font-size: 0.9rem;
        }

        footer {
            text-align: center;
            padding: 3rem 5%;
            border-top: 1px solid rgba(0, 212, 255, 0.1);
            color: var(--text-secondary);
            margin-top: 5rem;
        }

        @media (max-width: 768px) {
            nav ul {
                gap: 1.5rem;
            }

            .article-meta {
                flex-direction: column;
                gap: 0.5rem;
            }
        }
    </style>
</head>
<body>
    <nav>
        <ul>
            <li><a href="./#home">Home</a></li>
            <li><a href="./#about">About</a></li>
            <li><a href="./#blog">Blog</a></li>
            <li><a href="./#portfolio">Portfolio</a></li>
            <li><a href="./#contact">Contact</a></li>
        </ul>
    </nav>

    <article>
        <a href="./#blog" class="back-btn">‚Üê Back to Blog</a>

        <header class="article-header">
            <span class="article-category">Technical Deep-Dive</span>
            <h1>Dangerous Words in a Biotech Lab: "Let's just build a custom tool."</h1>
            
            <div class="article-meta">
                <span class="meta-item">üìÖ February 17, 2026</span>
                <span class="meta-item">‚è±Ô∏è 10 min read</span>
                <span class="meta-item">‚úçÔ∏è Mingsheng Qi, Ph.D.</span>
            </div>

            <p class="article-excerpt">
                Why the instinct to build custom bioinformatics tools often leads to Performance Jail‚Äîand when standardization beats innovation.
            </p>
        </header>

        <div class="article-content">
            <h2>Introduction</h2>

            <p>
                I've heard it in biotech hallways many times. It usually starts with a pipeline that's running a few hours too slow. The suggestion comes casually, sometimes over coffee: "The current tools don't fit our exact workflow. Let's just build our own."
            </p>

            <p>
                On the surface, it sounds like leadership. In reality, it's often the moment a project walks into Performance Jail.
            </p>

            <p>
                In bioinformatics, we suffer from a unique "Innovation Mirage." We think that because our science is cutting-edge, our software must be novel, too. But the truth is <strong>Standardization vs. Bespoke</strong>‚Äîthe choice between proven tools and custom solutions‚Äîdetermines whether your pipeline becomes an asset or a liability.
            </p>

            <h2>Respect the "Golden Stack"</h2>

            <p>
                We are currently operating on what I call the <strong>Golden Stack</strong>: BWA-MEM, GATK, and so on. These tools are the peer-reviewed, battle-tested infrastructure of modern genomics lasting more than 20 years.
            </p>

            <p>
                These tools have survived multiple waves of sequencing technology because their underlying mathematics are robust. When you use GATK, an FDA auditor or a peer reviewer doesn't ask anything. If you find a variant using a custom caller, they'll ask everything‚Äîand you'd better have answers.
            </p>

            <p>
                The hidden cost isn't just development time. It's the <strong>validation tax</strong>: every time you write a custom tool, you inherit the burden of proving it works as well as (or better than) the standard. That means benchmarking against known truth sets, publishing methods papers, responding to reviewer skepticism, and maintaining credibility in a field that rewards reproducibility.
            </p>

            <p>
                These tools have survived because standardization beats innovation for foundational infrastructure.
            </p>

            <h2>The Parabricks Paradigm: Acceleration Over Reinvention</h2>

            <p>
                The smartest move in the industry lately has been <strong>supercharging them</strong>. Look at <strong>NVIDIA Parabricks</strong>. NVIDIA re-implemented the math for GPUs. From a user perspective, it's functionally equivalent to the originals, but it runs faster.
            </p>

            <p>
                Crucially, Parabricks is now free. It proves that the value is in getting the <strong>standard results</strong> at the speed of modern business. They prioritized scientific validity while solving the engineering bottleneck. That is the opposite of "let's build something new because we can."
            </p>

            <p>
                This isn't anti-innovation. It's recognizing that innovation should happen at the layer where it matters: the biological question, the experimental design, the interpretation‚Äînot reimplementing the Burrows-Wheeler Transform because you're bored.
            </p>

            <h2>The "Free as in Puppy" Trap</h2>

            <p>
                We often choose to build or use a niche, "novel" tool because its initial price is $0. But in bioinformatics, <strong>"free" is usually "free as in a puppy."</strong>
            </p>

            <p>
                It's free to take home, but you are now the permanent support lead when a Linux kernel update or a Python library shift breaks the code.
            </p>

            <p>
                When the PhD student who wrote the tool leaves, or the GitHub repository from a 2023 paper goes dark, that "free" tool becomes a black box. If you build a custom tool to do what a standard tool already does, you're just adopting a high-maintenance puppy that eventually becomes a liability‚Äîespecially if you're in a regulated environment or your stakeholders require reproducibility and auditability.
            </p>

            <h2>Why Do We Keep Building Anyway?</h2>

            <p>
                If the case for standardization is so strong, why do we keep reinventing the wheel?
            </p>

            <h3>1. The "Perfect Fit" Illusion</h3>

            <p>
                "The standard tool doesn't do exactly what we need!" Sometimes true. But often, the gap between "what the standard does" and "what we think we need" is smaller than the cost of building and maintaining the alternative.
            </p>

            <p>
                Ask yourself: Is the mismatch a fundamental limitation, or just a configuration issue? Can you preprocess inputs or postprocess outputs to bridge the gap? Would a simple wrapper script solve 90% of the problem?
            </p>

            <h3>2. The Engineer's Itch</h3>

            <p>
                We're technologists. Building is fun. Using someone else's tool feels like giving up control. But science isn't about control‚Äîit's about validity. And in production genomics, reliability beats novelty every time.
            </p>

            <p>
                If you're building a tool because it's intellectually satisfying rather than operationally necessary, you're optimizing for the wrong thing.
            </p>

            <h3>3. The "Not Invented Here" Syndrome</h3>

            <p>
                Organizations sometimes distrust external tools simply because they weren't built in-house. This is especially common in companies with strong engineering cultures‚Äî"we're smarter than the open-source community, we can do better."
            </p>

            <p>
                Rarely true. The Broad Institute has more person-years invested in GATK than your three-person bioinformatics team will ever accumulate.
            </p>

            <h3>4. Genuine Innovation (Rare)</h3>

            <p>
                Sometimes you actually need something new. You're doing science no one has done before. The standard tools genuinely don't apply.
            </p>

            <p>
                Examples:
            </p>

            <ul>
                <li>Novel modalities (spatial transcriptomics, long-read single-cell)</li>
                <li>Proprietary assay chemistry requiring custom QC</li>
                <li>Unique organism/system with no reference tools</li>
            </ul>

            <p>
                But even here, the question isn't "should we build?" It's "what's the smallest tool we can build that leverages as much existing infrastructure as possible?"
            </p>

            <h2>When Custom Tools Are Justified</h2>

            <p>
                Let me be clear: I'm not anti-custom-tool. I've built plenty. But they need to clear a high bar.
            </p>

            <h3>Justified Use Cases:</h3>

            <p>
                <strong>1. Glue Code / Workflow Automation</strong><br>
                You're not replacing GATK‚Äîyou're wrapping it. Nextflow pipelines, Snakemake workflows, custom scripts that orchestrate standard tools‚Äîabsolutely yes. This is infrastructure, not reinvention.
            </p>

            <p>
                <strong>2. Domain-Specific Preprocessing</strong><br>
                Your assay generates data in a non-standard format. You write a parser to convert it into standard FASTQ/BAM/VCF that feeds into standard downstream tools. Totally reasonable.
            </p>

            <p>
                <strong>3. Visualization and Reporting</strong><br>
                Standard tools generate numbers. You need plots, dashboards, stakeholder-friendly reports. Custom R Shiny apps, Python Streamlit dashboards‚Äîthese add value without replacing validated analytics.
            </p>

            <p>
                <strong>4. Truly Novel Algorithms (with a plan to publish)</strong><br>
                You've developed a new statistical method that genuinely outperforms existing approaches. You build a proof-of-concept tool. Great‚Äîbut you'd better have a validation plan, benchmark datasets, and a publication timeline. If it works, open-source it and let the community vet it. If it becomes widely adopted, it might join the Golden Stack.
            </p>

            <p>
                <strong>5. Performance Optimization for Scale</strong><br>
                You're processing 100,000 samples, and the standard tool is too slow. Fine‚Äîbut consider commercial accelerated versions first (like Parabricks). If you still need to optimize, profile carefully, and optimize only the bottleneck, not the whole stack.
            </p>

            <h2>A Framework: Build vs. Buy vs. Borrow</h2>

            <p>
                Before writing a single line of code, ask:
            </p>

            <h3>Can I <strong>Borrow</strong> (use existing open-source tool)?</h3>

            <ul>
                <li>Is there a standard tool that does this?</li>
                <li>What percentage of my needs does it cover?</li>
                <li>What's the validation status (publications, user base)?</li>
            </ul>

            <h3>Can I <strong>Buy</strong> (use commercial/SaaS tool)?</h3>

            <ul>
                <li>What's the total cost of ownership vs. building?</li>
                <li>Does it integrate with our infrastructure?</li>
                <li>Is support included? What's the SLA?</li>
            </ul>

            <h3>Should I <strong>Build</strong>?</h3>

            <p>
                Only if:
            </p>

            <ul>
                <li>Neither borrow nor buy options exist or are viable</li>
                <li>The custom solution provides measurable value (faster, cheaper, better) AND</li>
                <li>You have a maintenance plan (who owns it? how is it documented? how will it be tested?)</li>
            </ul>

            <p>
                If the answer to "should I build?" is yes, then ask: <strong>What's the minimum viable tool?</strong>
            </p>

            <p>
                Don't build a Swiss Army knife. Build a scalpel. Solve the one problem you have, using as much existing infrastructure as possible.
            </p>

            <h2>The Hidden Costs of Custom Tools</h2>

            <p>
                When you build a custom tool, you're not just writing code. You're taking on:
            </p>

            <h3>1. Maintenance Burden</h3>

            <p>
                Software decays. Dependencies update. APIs change. Bugs emerge. Someone needs to fix these‚Äîforever. Who?
            </p>

            <h3>2. Documentation Debt</h3>

            <p>
                If you don't document it, no one else can use it. If only one person understands it, you have a bus factor of one.
            </p>

            <h3>3. Training Overhead</h3>

            <p>
                Every new team member needs to learn your custom tool. With standard tools, they might already know them‚Äîor there are tutorials, courses, and StackOverflow answers.
            </p>

            <h3>4. Validation and Trust Tax</h3>

            <p>
                Stakeholders trust standard tools because they're peer-reviewed and widely used. Your custom tool starts at zero trust. You need benchmarks, comparisons, validation datasets‚Äîand you need to defend every choice.
            </p>

            <h3>5. Opportunity Cost</h3>

            <p>
                The time spent building, debugging, and maintaining custom tools is time not spent analyzing data, optimizing workflows, or answering biological questions.
            </p>

            <h2>Case Study: The $200K Custom Variant Caller</h2>

            <p>
                At a previous biotech company, a team decided GATK's HaplotypeCaller was "too slow" for their production pipeline. They spent 6 months and ~$200K building a custom variant caller, claiming it was 5x faster.
            </p>

            <p>
                Initial benchmarks looked good. They deployed it.
            </p>

            <p>
                Six months later:
            </p>

            <ul>
                <li>FDA reviewers questioned the validation</li>
                <li>Wet-lab collaborators found discrepancies vs. published data</li>
                <li>The original developer left the company</li>
                <li>No one else understood the codebase well enough to debug edge cases</li>
            </ul>

            <p>
                The team spent another $150K re-validating, documenting, and ultimately... switching back to GATK (now accelerated with Parabricks, which solved the speed issue without the validation nightmare).
            </p>

            <p>
                <strong>Total sunk cost: ~$350K and 12 months.</strong>
            </p>

            <p>
                <strong>Lesson:</strong> Speed is useless if no one trusts your results.
            </p>

            <h2>Principles for Responsible Tool Development</h2>

            <p>
                If you decide you genuinely need a custom tool, follow these principles:
            </p>

            <h3>1. Start with a Prototype</h3>

            <p>
                Build the simplest version that proves the concept. Get feedback. Iterate. Don't over-engineer from day one.
            </p>

            <h3>2. Benchmark Against Standards</h3>

            <p>
                Your tool must be measurably better (faster, more accurate, cheaper) than alternatives. Publish comparisons. Be honest about tradeoffs.
            </p>

            <h3>3. Document from Day One</h3>

            <p>
                README, usage examples, parameter explanations, FAQs. If you wouldn't want to debug this code in 2 years, write better docs now.
            </p>

            <h3>4. Write Tests</h3>

            <p>
                Unit tests, integration tests, regression tests. If it's not tested, assume it's broken.
            </p>

            <h3>5. Plan for Maintenance</h3>

            <p>
                Who owns this tool? What happens when the original developer leaves? Is there a handoff plan? Is it modular enough that someone else can understand it?
            </p>

            <h3>6. Open Source (When Possible)</h3>

            <p>
                Open-sourcing forces you to write better code, better docs, and better tests. The feedback loop from external users is invaluable. And if it's truly useful, others will help maintain it.
            </p>

            <h2>The "Innovation Paradox" in Genomics</h2>

            <p>
                Here's the paradox: the best bioinformatics teams are both <strong>highly innovative</strong> and <strong>deeply conservative</strong>.
            </p>

            <p>
                <strong>Innovative</strong> in experimental design, biological hypotheses, analysis approaches, and visualization.
            </p>

            <p>
                <strong>Conservative</strong> in foundational infrastructure‚Äîalignment, variant calling, quality control. They don't reinvent the wheel here. They use the Golden Stack because it works, because it's trusted, and because their time is better spent on problems that matter.
            </p>

            <p>
                The worst teams do the opposite: conservative in science, innovative in infrastructure. They run standard experiments but insist on building custom pipelines from scratch‚Äîusually because "we wanted to learn" or "we didn't trust the standard tools."
            </p>

            <p>
                That's how you end up with a custom tool that does exactly what GATK does, except slower, buggier, and with zero external validation.
            </p>

            <h2>What I Do Instead: A Pragmatic Approach</h2>

            <p>
                Here's my personal heuristic for bioinformatics tool decisions:
            </p>

            <h3>Tier 1: Core Algorithms (Alignment, Variant Calling, Quantification)</h3>

            <p>
                <strong>Default to standard tools.</strong> Period. BWA-MEM, GATK, STAR, featureCounts, etc. If speed is an issue, use accelerated versions (Parabricks, commercial cloud tools). Do not rewrite these unless you're publishing a methods paper and have a validation plan.
            </p>

            <h3>Tier 2: Workflow and Orchestration</h3>

            <p>
                <strong>Build lightweight glue code.</strong> Nextflow, Snakemake, custom scripts that orchestrate standard tools. Keep it modular, documented, tested. This is where custom code is not just acceptable but necessary.
            </p>

            <h3>Tier 3: Analysis and Interpretation</h3>

            <p>
                <strong>Mix of standard and custom.</strong> Use standard statistical frameworks (DESeq2, limma, scanpy) where possible. Build custom scripts for domain-specific analysis, but structure them as report-generating notebooks (R Markdown, Jupyter) that document logic transparently.
            </p>

            <h3>Tier 4: Visualization and Dashboards</h3>

            <p>
                <strong>Heavily custom, but reusable.</strong> Build Streamlit dashboards, R Shiny apps, Plotly visualizations. These don't replace analytic tools‚Äîthey make results accessible. Totally worth the investment.
            </p>

            <h3>Tier 5: True Novelty</h3>

            <p>
                <strong>Rare, but when needed, go all in.</strong> If you're pioneering a new method, build the tool, write the paper, open-source it, support it. But recognize this is a major commitment, not a side project.
            </p>

            <h2>Final Thoughts: Choose Your Battles</h2>

            <p>
                Not every problem needs a novel solution. In fact, most don't.
            </p>

            <p>
                The genomics field has spent two decades building, refining, and validating an incredible toolkit. Yes, there are gaps. Yes, there are inefficiencies. But the cost of ignoring that infrastructure and building everything from scratch is almost always higher than you think.
            </p>

            <p>
                So the next time someone in your lab says, <strong>"Let's just build a custom tool,"</strong> pause. Ask:
            </p>

            <ul>
                <li>What problem are we solving?</li>
                <li>Does an existing tool solve 80%+ of it?</li>
                <li>Can we adapt, wrap, or extend existing tools instead of replacing them?</li>
                <li>If we build this, who will maintain it in 2 years?</li>
                <li>Is this the best use of our time?</li>
            </ul>

            <p>
                Sometimes the answer is genuinely "yes, we need to build this." But most of the time, the answer is: <strong>"No, let's use the standard tool and spend our time on the science."</strong>
            </p>

            <blockquote>
                "Because in the end, the best tool is the one that lets you answer your biological question faster, cheaper, and with more confidence. And that's almost never the tool you built last Tuesday."
            </blockquote>
        </div>

        <div class="share-section">
            <h3>Share this post</h3>
            <div class="share-buttons">
                <a href="#" class="share-btn">üê¶ Twitter</a>
                <a href="#" class="share-btn">üíº LinkedIn</a>
                <a href="#" class="share-btn">üìß Email</a>
            </div>
        </div>

        <div class="related-posts">
            <h3>Related Posts</h3>
            <div class="related-grid">
                <a href="./blog-reproducible-pipelines.html" class="related-card">
                    <h4>The ROI of Reproducible Pipelines</h4>
                    <p>Why investing in automated workflows isn't just good science‚Äîit's good business.</p>
                </a>
                <a href="./blog-kpis.html" class="related-card">
                    <h4>Designing KPIs for Genomics Operations</h4>
                    <p>Metrics that predict bottlenecks and keep pipelines running smoothly.</p>
                </a>
                <a href="./blog-skim-seq.html" class="related-card">
                    <h4>Skim-Seq + Imputation</h4>
                    <p>Cost-effective genotyping using standard tools at scale.</p>
                </a>
            </div>
        </div>
    </article>

    <footer>
        <p>&copy; 2026 Mingsheng Qi, Ph.D. | <a href="./" style="color: var(--accent-blue); text-decoration: none;">Return to Home</a></p>
    </footer>
</body>
</html>
